Cargando…
Cross-over—it's a feature, not a bug
Pharmaceutical companies, investigators, regulators, and payers need to work together to adapt standards for drug development that meet the needs of all stakeholders, but first and foremost, benefit cancer patients in the most appropriate way.
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551154/ https://www.ncbi.nlm.nih.gov/pubmed/26078468 http://dx.doi.org/10.1093/annonc/mdv260 |